BioCentury
ARTICLE | Company News

ACTI licenses OxiGene compound

November 26, 2001 8:00 AM UTC

OxiGene (OXGN; SSE:OXGN) non-exclusively licensed its benzamide technology platform, except for OXGN's Declopramide, to Active Biotech (SEE:ACTI) in exchange for milestones and royalties. Under a 1999...